Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 May 2:14:1380584.
doi: 10.3389/fonc.2024.1380584. eCollection 2024.

KRAS G12C inhibitor combination therapies: current evidence and challenge

Hirotaka Miyashita  1 , Shumei Kato  2 , David S Hong  3
Affiliations
Review

KRAS G12C inhibitor combination therapies: current evidence and challenge

Hirotaka Miyashita et al. Front Oncol. .

Abstract

Although KRAS G12C inhibitors have proven that KRAS is a "druggable" target of cancer, KRAS G12C inhibitor monotherapies have demonstrated limited clinical efficacy due to primary and acquired resistance mechanisms. Multiple combinations of KRAS G12C inhibitors with other targeted therapies, such as RTK, SHP2, and MEK inhibitors, have been investigated in clinical trials to overcome the resistance. They have demonstrated promising efficacy especially by combining KRAS G12C and EGFR inhibitors for KRAS G12C-mutated colorectal cancer. Many clinical trials of combinations of KRAS G12C inhibitors with other targeted therapies, such as SOS1, ERK, CDK4/6, and wild-type RAS, are ongoing. Furthermore, preclinical data have suggested additional promising KRAS G12C combinations with YAP/TAZ-TEAD inhibitors, FAK inhibitors, and farnesyltransferase inhibitors. The combinations of KRAS G12C inhibitors with immunotherapies and chemotherapies have also been investigated, and the preliminary results were reported. More recently, KRAS-targeted therapies not limited to KRAS G12C are being developed, potentially broadening the treatment landscape of KRAS-mutated cancers. Rationally combining KRAS inhibitors with other therapeutics is likely to play a significant role in future treatment for KRAS-mutated solid tumors.

Keywords: KRAS; KRAS G12C inhibitors; MAPK; RTK inhibitors; combination (combined) therapy; immunotherapy; mTOR.

PubMed Disclaimer

Conflict of interest statement

SK serves as a consultant for Medpace, Foundation Medicine, NeoGenomics and CureMatch. He receives speaker’s fee from Roche/Genentech and Bayer, and advisory board for Pfizer. He has research funding from ACT Genomics, Sysmex, Konica Minolta, OmniSeq, Personalis and Function Oncology. DH discloses the following that could be potential conflict of interest: Research (Inst)/Grant Funding (Inst) AbbVie, Adaptimmune, Adlai-Nortye, Amgen, Astelles, Astra-Zeneca, Bayer, Biomea, Bristol-Myers Squibb, Daiichi-Sankyo, Deciphera, Eisai, Eli Lilly, Endeavor, Erasca, F. Hoffmann-LaRoche, Fate Therapeutics, Genentech, Genmab, Immunogenesis, Infinity, Kyowa Kirin, Merck, Mirati, Navier, NCI-CTEP, Novartis, Numab, Pfizer, Pyramid Bio, Revolution Medicine, SeaGen, STCube, Takeda, TCR2, Turning Point Therapeutics, VM Oncology. Travel, Accommodations, Expenses: AACR, ASCO, CLCC, Bayer, Genmab, SITC, Telperian. Consulting, Speaker, or Advisory Role: 28Bio, Abbvie, Acuta, Adaptimmune, Alkermes, Alpha Insights, Amgen, Affini-T, Astellas, Aumbiosciences, Axiom, Baxter, Bayer, Boxer Capital, BridgeBio, CARSgen, CLCC, COG, COR2ed, Cowen, Ecor1, EDDC, Erasca, Exelixis, Fate Therapeutics, F.Hoffmann-La Roche, Genentech, Gennao Bio, Gilead, GLG, Group H, Guidepoint, HCW Precision Oncology, Immunogenesis, Incyte Inc, Inhibrix Inc, InduPro, Janssen, Jounce Therapeutics Inc,Lan- Bio, Liberium, MedaCorp, Medscape, Novartis, Numab, Oncologia Brasil, ORI Capital, Pfizer, Pharma Intelligence, POET Congress, Prime Oncology, Projects in Knowledge, Quanta, RAIN, Ridgeline, Revolution Medicine SeaGen, Stanford, STCube, Takeda, Tavistock, Trieza Therapeutics,T-Knife, Turning Point Therapeutics, WebMD, YingLing Pharma, Ziopharm. Other ownership interests: Molecular Match (Advisor), OncoResponse (Founder, Advisor), Telperian (Founder, Advisor). The remaining author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
KRAS G12C signaling pathways and medications under trial in combination with KRAS G12C inhibitors. The activating and inhibiting signaling are expressed by pointed head and blunt head arrows, respectively. Arrows with broken lines mean a multi-step effect rather than a direct effect. Medications to target KRAS G12C are listed in yellow boxes. Medications in red boxes are being investigated in clinical trials as combination treatments with KRAS G12C inhibitors. Medications in green boxes are not currently in clinical trials but have the potential to be combined with KRAS G12C inhibitors based on preclinical evidence. Created with BioRender.com.
See this image and copyright information in PMC

References

    1. Kirsten W, Mayer L. Morphologic responses to a murine erythroblastosis virus. J Natl Cancer Inst. (1967) :311–35. doi: 10.1093/jnci/39.2.311 - DOI - PubMed
    1. Muzny DM, Bainbridge MN, Chang K, Dinh HH, Drummond JA, Fowler G, et al. . Comprehensive molecular characterization of human colon and rectal cancer. Nature. (2012) 487:330–7. doi: 10.1038/NATURE11252 - DOI - PMC - PubMed
    1. Collisson EA, Campbell JD, Brooks AN, Berger AH, Lee W, Chmielecki J, et al. . Comprehensive molecular profiling of lung adenocarcinoma. Nature. (2014) 511:543–50. doi: 10.1038/NATURE13385 - DOI - PMC - PubMed
    1. Raphael BJ, Hruban RH, Aguirre AJ, Moffitt RA, Yeh JJ, Stewart C, et al. . Integrated genomic characterization of pancreatic ductal adenocarcinoma. Cancer Cell. (2017) 32:185–203.e13. doi: 10.1016/J.CCELL.2017.07.007 - DOI - PMC - PubMed
    1. Malumbres M, Barbacid M. RAS oncogenes: the first 30 years. Nat Rev Cancer. (2003) 3:459–65. doi: 10.1038/NRC1097 - DOI - PubMed